Malvern life sciences company halts late-stage study of new drug candidate
June 02, 2020 at 13:47 PM EDT
The company will now focus on its gene therapy candidates for retinal disorders.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|